Shenshuai Yingyang Jiaonang ameliorates chronic kidney disease-associated muscle atrophy in rats by inhibiting ferroptosis mediated by the HIF-1α/SLC7A11 pathway

• DOI: 10.1016/j.heliyon.2024.e29093
• Publication Date: 2024-04-15T14:24:48Z
• Authors: Liliang Ju; Jianxin Diao; Jiaxing Zhang; Fahong Dai; Hong Zhou; Zhongxiao Han; Rong Hu; Tingting Pei; Fujing Wang; Zhuoen He; Xiuqiong Fu; Mingqing Wang; Wei Xiao; Yun Ma
• Keywords: Muscle Atrophy

ObjectiveShenshuai Yingyang Jiaonang (SSYYJN), a traditional Chinese medicine formula, can ameliorate muscle atrophy associated with chronic kidney disease (CKD). However, its mechanisms of action remain unclear. This study is to investigate the molecular involved in effects SSYYJN ameliorating CKD rats. Methods: The chemical compounds were identified by UPLC-Q-Orbitrap HRMS. Considering dose-response relationship compounds, male SD rats randomly divided into Sham, Model, SSYYJN, and α-Keto Acid (KA) groups. Subsequently, we assessed therapeutic anti-ferroptotic SSYYJN. Network pharmacology studies used predict mechanism on ferroptosis further verified for accuracy.ResultsA total 42 active from alleviated caused CKD, as evidenced changes body weight, serum biochemical indices, mass histopathology skeletal muscle, levels MuRF1. reduced iron, MDA, ROS, increased GSH, NAPDH, Gpx4. analysis indicated that exerted closely related HIF-1α signaling pathway. Molecular protein genetic test results showed SLC7A11.ConclusionsSSYYJN attenuates inhibiting through activation HIF-1α/SLC7A11 pathway might be promising CKD.